When: Daily close above $90.90 (10-EMA) with positive MACD histogram AND volume >3.5M shares

Then: Upgrade to Overweight

When: Gross margin ≥60% AND disciplined FY27 input-cost guidance

Then: Upgrade to Overweight

When: Operating margin below 18% with elevated input-cost disclosure AND 200-SMA break

Then: Downgrade to Underweight at 70–75% sizing

When: Confirmed weekly close below $87.19 with volume >5M shares

Then: Downgrade to Sell, reassess at $84.50 spring-low retest

Trim 25-40% of the position on rallies toward $90-91, reduce portfolio weight to 2% or less, and maintain a defined stop at $87.19 weekly close. Follow the plan as written - controlled reduction with disciplined risk parameters rather than full liquidation at support.

• CL has raised its dividend for over 60 consecutive years with a 2.44% yield growing at 5-7% annually, compounding meaningfully over time versus static 5% Treasury yield
• 200-SMA at $87.89 is meaningful support for low-beta defensive names like CL (beta 0.32) - attracts institutional buyers like pension funds and dividend-focused mandates mechanically
• ATR compressed at 1.83 - volatility expansion could occur in either direction, and selling at support gambles on the direction without confirmation
• Divestiture proceeds (estimated $800M to $1.2B) will be redeployed via buybacks and dividends, creating a discrete re-rating event opportunity
• Stock has already sold off from $99 to $87 - bad news substantially priced in; the market is already discounting FX and input cost headwinds
• Aggressive thesis treats every risk factor as confirmation of bearish view (confirmation bias) rather than balanced risk assessment
• Consumer staples historically outperform in late-cycle tightening phases and serve as flight-to-safety in volatile regimes
• The plan already represents meaningful derisking - trimming 25-40% and reducing to 2% weight is conservative, not a hold thesis

→ vs aggressive: Misapplies high-beta technical analysis (200-SMA) to a defensive low-beta name (beta 0.32), arriving at wrong conclusion about support significance

→ vs aggressive: Selling at compressed ATR (1.83) right at 200-SMA support ($87.89) is gambling with capital - volatility expansion could equally produce violent reversal as breakdown

→ vs aggressive: Compares 2.44% yield to 5% Treasury without accounting for duration risk, inflation risk, and CL's 60+ year dividend growth trajectory

→ vs aggressive: Full exit removes option value of position and exposes firm to whipsaw risk if CL reverses on divestiture announcement or stabilization data

→ vs aggressive: The RBC 2027 stabilization thesis requires only two quarterly earnings cycles (Q3 2026 late October, Q4 2026 late January/early February) to confirm - not an abstract distant future

→ vs aggressive: Parking proceeds in Treasuries creates negative carry on the relative trade - missing 9% upside to $95 while earning 5% is suboptimal

Execute the existing plan as written: hold at current levels awaiting volatility expansion, trim 25-40% on rallies to $90-91, maintain $87.19 stop loss, reduce to ≤2% portfolio weight, avoid initiating new longs, and maintain defensive allocation through ETFs rather than concentrated CL position.

• Current price at $87.89 is 0.8% above 200-SMA support with compressed ATR of 1.83 indicating imminent volatility expansion—selling into this setup is timing risk disguised as risk management
• Plan already encodes the balanced view: trim 25-40% on rallies to $90-91, exit fully on weekly close below $87.19, reduce to ≤2% portfolio weight, no new longs
• Forward P/E of 21.4x on 5% revenue growth with PEG above 2x is expensive, but 3% to 2% weight reduction preserves position convexity and option value
• The 200-SMA on a 0.32 beta defensive name has structural significance due to pension funds, dividend mandates, and institutional rebalancers—different buyer profile than high-beta tech stocks
• Divestiture proceeds of $1B on $70B market cap is 1.4% incremental capital return—a maintenance event, not a re-rating catalyst
• Q3 earnings will face headwinds from strong dollar and elevated input costs, making it a poor confirmation setup for the stabilization thesis
• Cleaner defensive exposure available through ETFs rather than a concentrated position sitting on critical support with impaired yield advantage

→ vs aggressive: Advocating full liquidation at $87.89 contradicts the trader's own plan which explicitly calls for trims on rallies toward $90-91—not current levels; selling at support is the worst execution of a fundamentally sound view

→ vs aggressive: The '200-SMA is just lagging math' argument ignores how low-beta consumer staples trade—pension funds and institutional rebalancers treat it as structural support due to their mandates

→ vs conservative: The 'institutional buyers will defend 200-SMA' thesis is a theory tested in real time, not a guarantee—CL already dropped 11% from $99 to $87 in a 0.32 beta name

→ vs conservative: Waiting for Q3 earnings confirmation risks exiting at a worse level if the stock breaks the 200-SMA before earnings confirm the stabilization thesis